3.連結財務諸表及び主な注記

(1)連結貸借対照表

 

 

(単位:千円)

 

前連結会計年度

(2025年3月31日)

当連結会計年度

(2026年3月31日)

資産の部

 

 

流動資産

 

 

現金及び預金

23,592,676

27,760,027

受取手形

243,962

電子記録債権

35,486

売掛金

26,498,203

31,413,406

商品及び製品

8,592,660

10,994,264

仕掛品

2,352,119

3,551,515

原材料及び貯蔵品

5,489,107

6,351,030

その他

2,892,079

3,200,118

貸倒引当金

131,114

658,965

流動資産合計

69,529,694

82,646,882

固定資産

 

 

有形固定資産

 

 

建物及び構築物

26,531,377

27,941,819

減価償却累計額

19,913,607

20,835,015

建物及び構築物(純額)

6,617,770

7,106,803

機械装置及び運搬具

16,800,871

18,657,215

減価償却累計額

15,147,512

15,726,455

機械装置及び運搬具(純額)

1,653,359

2,930,759

土地

12,658,498

12,663,993

建設仮勘定

3,617,496

2,905,397

その他

7,458,612

8,062,076

減価償却累計額

5,364,292

6,069,647

その他(純額)

2,094,319

1,992,428

有形固定資産合計

26,641,444

27,599,383

無形固定資産

 

 

のれん

3,621,171

3,027,507

販売権

27,950,775

27,088,898

商標権

7,641,312

7,821,831

その他

1,148,423

1,643,550

無形固定資産合計

40,361,683

39,581,788

投資その他の資産

 

 

投資有価証券

8,865,571

10,112,376

繰延税金資産

97,940

84,760

退職給付に係る資産

13,264,717

19,294,530

その他

443,262

407,314

貸倒引当金

32,717

29,086

投資その他の資産合計

22,638,773

29,869,895

固定資産合計

89,641,902

97,051,067

資産合計

159,171,596

179,697,949

 

 

 

 

(単位:千円)

 

前連結会計年度

(2025年3月31日)

当連結会計年度

(2026年3月31日)

負債の部

 

 

流動負債

 

 

買掛金

3,971,467

4,895,991

短期借入金

34,298,379

33,834,190

未払法人税等

3,773,088

4,827,849

賞与引当金

1,623,664

1,778,324

その他

10,782,461

10,371,773

流動負債合計

54,449,062

55,708,129

固定負債

 

 

長期借入金

6,865,780

5,269,740

繰延税金負債

6,496,077

8,586,947

退職給付に係る負債

224,138

201,368

資産除去債務

56,451

56,629

その他

1,283,058

1,270,343

固定負債合計

14,925,506

15,385,029

負債合計

69,374,568

71,093,159

純資産の部

 

 

株主資本

 

 

資本金

6,593,398

6,593,398

資本剰余金

11,685,121

5,620,541

利益剰余金

67,207,063

73,545,791

自己株式

18,266,472

12,204,622

株主資本合計

67,219,110

73,555,108

その他の包括利益累計額

 

 

その他有価証券評価差額金

2,108,422

3,069,779

為替換算調整勘定

16,995,687

24,628,069

退職給付に係る調整累計額

3,216,617

7,143,784

その他の包括利益累計額合計

22,320,727

34,841,632

非支配株主持分

257,189

208,048

純資産合計

89,797,027

108,604,790

負債純資産合計

159,171,596

179,697,949

 

E0094845590ゼリア新薬工業株式会社Zeria Pharmaceutical Co., Ltd.通期第1号参考様式 [日本基準](連結)Japan GAAPtrueCTECTE2025-04-012026-03-31FY2026-03-312024-04-012025-03-312025-03-311falsefalsefalse455902026-03-31jppfs_cor:CapitalStockMember455902025-04-012026-03-31jppfs_cor:ShareholdersEquityMember455902026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902026-03-31jppfs_cor:NonControllingInterestsMember455902025-04-012026-03-31jppfs_cor:CapitalStockMember455902025-04-012026-03-31jppfs_cor:CapitalSurplusMember455902025-04-012026-03-31jppfs_cor:RetainedEarningsMember455902025-04-012026-03-31jppfs_cor:TreasuryStockMember455902024-03-31455902026-05-08455902026-03-31455902025-04-012026-03-31455902025-03-31455902024-04-012025-03-31455902025-03-31jppfs_cor:CapitalStockMember455902025-03-31jppfs_cor:CapitalSurplusMember455902025-03-31jppfs_cor:RetainedEarningsMember455902025-03-31jppfs_cor:TreasuryStockMember455902025-03-31jppfs_cor:ShareholdersEquityMember455902025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902025-03-31jppfs_cor:NonControllingInterestsMember455902026-03-31jppfs_cor:CapitalSurplusMember455902026-03-31jppfs_cor:RetainedEarningsMember455902026-03-31jppfs_cor:TreasuryStockMember455902026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-04-012026-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902024-04-012025-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902024-03-31jppfs_cor:RemeasurementsOfDefinedBenefitPlansMember455902025-04-012026-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902025-04-012026-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902025-04-012026-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902025-04-012026-03-31jppfs_cor:NonControllingInterestsMember455902026-03-31jppfs_cor:ShareholdersEquityMember455902024-04-012025-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902026-03-31jpcrp_cor:ReconcilingItemsMember455902025-04-012026-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902025-04-012026-03-31jpcrp_cor:ReconcilingItemsMember455902025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902025-03-31jpcrp_cor:ReconcilingItemsMember455902024-04-012025-03-31jpcrp_cor:TotalOfReportableSegmentsAndOthersMember455902024-04-012025-03-31jpcrp_cor:ReconcilingItemsMember455902024-03-31jppfs_cor:CapitalStockMember455902024-03-31jppfs_cor:CapitalSurplusMember455902024-03-31jppfs_cor:RetainedEarningsMember455902026-03-31jpcrp_cor:ReportableSegmentsMember455902026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902025-04-012026-03-31jpcrp_cor:ReportableSegmentsMember455902025-04-012026-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902025-03-31jpcrp_cor:ReportableSegmentsMember455902025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902024-04-012025-03-31jpcrp_cor:ReportableSegmentsMember455902024-04-012025-03-31jpcrp_cor:OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember455902026-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902026-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902025-04-012026-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902025-04-012026-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902025-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902025-03-31tse-acedjpfr-45590:ConsumerHealthCareBusinessReportableSegmentsMember455902024-04-012025-03-31tse-acedjpfr-45590:EthicalDrugBusinessReportableSegmentsMember455902024-03-31jppfs_cor:TreasuryStockMember455902024-03-31jppfs_cor:ShareholdersEquityMember455902024-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902024-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902024-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902024-03-31jppfs_cor:NonControllingInterestsMember455902024-04-012025-03-31jppfs_cor:RetainedEarningsMember455902024-04-012025-03-31jppfs_cor:CapitalStockMember455902024-04-012025-03-31jppfs_cor:CapitalSurplusMember455902024-04-012025-03-31jppfs_cor:TreasuryStockMember455902024-04-012025-03-31jppfs_cor:ShareholdersEquityMember455902024-04-012025-03-31jppfs_cor:ValuationDifferenceOnAvailableForSaleSecuritiesMember455902024-04-012025-03-31jppfs_cor:ForeignCurrencyTranslationAdjustmentMember455902024-04-012025-03-31jppfs_cor:ValuationAndTranslationAdjustmentsMember455902024-04-012025-03-31jppfs_cor:NonControllingInterestsMemberxbrli:pureiso4217:JPY